Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience.

Roerden M, Walz JS, Müller MR, Sökler M, Federmann B, Kanz L, Bethge W, Vogel W.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2595-2604. doi: 10.1007/s00432-019-02999-9. Epub 2019 Aug 13.

PMID:
31410605
2.

Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner.

Jahnke S, Schmid H, Secker KA, Einhaus J, Duerr-Stoerzer S, Keppeler H, Schober-Melms I, Baur R, Schumm M, Handgretinger R, Bethge W, Kanz L, Schneidawind C, Schneidawind D.

Front Immunol. 2019 Jul 9;10:1542. doi: 10.3389/fimmu.2019.01542. eCollection 2019.

3.

Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.

Frauenfeld L, Bonzheim I, Wirths S, Steinhilber J, Horger M, Mankel B, Bethge W, Fend F, Federmann B.

Virchows Arch. 2019 Jul 17. doi: 10.1007/s00428-019-02608-7. [Epub ahead of print]

PMID:
31317311
4.

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.

Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R.

Lancet Haematol. 2019 Aug;6(8):e409-e418. doi: 10.1016/S2352-3026(19)30088-2. Epub 2019 Jun 24.

PMID:
31248843
5.

IMPULS: Impulsivity-Focused Group Intervention to Reduce Binge Eating Episodes in Patients with Binge Eating Disorder - A Randomised Controlled Trial.

Schag K, Rennhak SK, Leehr EJ, Skoda EM, Becker S, Bethge W, Martus P, Zipfel S, Giel KE.

Psychother Psychosom. 2019;88(3):141-153. doi: 10.1159/000499696. Epub 2019 May 20.

PMID:
31108488
6.

Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, Wirths S, Moehle R, Faul C, Kanz L, Axt S, Bethge WA.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0544-y. [Epub ahead of print]

PMID:
31089279
7.

G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.

Schneidawind C, Jahnke S, Schober-Melms I, Schumm M, Handgretinger R, Faul C, Kanz L, Bethge W, Schneidawind D.

Br J Haematol. 2019 Jul;186(1):60-71. doi: 10.1111/bjh.15881. Epub 2019 Mar 27.

PMID:
30916396
8.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.

9.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano AM, Messina G, Bethge W, Herrera P, Sureda A, Carella AM, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N.

Lancet Haematol. 2019 Feb;6(2):e89-e99. doi: 10.1016/S2352-3026(18)30214-X. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

PMID:
30709437
10.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP.

Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140. doi: 10.1016/j.bbmt.2019.01.016. Epub 2019 Jan 15. Review.

PMID:
30658222
11.

Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.

Schneidawind C, Hagmaier V, Faul C, Kanz L, Bethge W, Schneidawind D.

Ann Hematol. 2018 Dec;97(12):2491-2500. doi: 10.1007/s00277-018-3454-y. Epub 2018 Jul 31.

PMID:
30066039
12.

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Ayuk F, Beelen DW, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner EM, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn PA, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2558-2567. doi: 10.1016/j.bbmt.2018.06.026. Epub 2018 Jul 24.

PMID:
29966760
13.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.

Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kröger N, Montoto S, Schetelig J.

Bone Marrow Transplant. 2019 Jan;54(1):44-52. doi: 10.1038/s41409-018-0207-4. Epub 2018 May 4.

PMID:
29728701
14.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
15.

Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma.

Heinzelmann F, Bethge W, Beelen DW, Stelljes M, Dreger P, Engelhard M, Finke J, Kröger N, Holler E, Bornhäuser M, Müller A, Haubitz I, Ottinger H.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1173-1183. doi: 10.1007/s00432-018-2633-5. Epub 2018 Apr 5.

PMID:
29623467
16.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

17.

Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation.

Katz MC, Michaelis S, Siegmund DM, Koch R, Bethge W, Handgretinger R, Mezger M.

Bone Marrow Transplant. 2018 Apr;53(4):377-382. doi: 10.1038/s41409-017-0059-3. Epub 2018 Jan 12. No abstract available.

PMID:
29330404
18.

Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.

Bar M, Flowers MED, Storer BE, Chauncey TR, Pulsipher MA, Thakar MS, Bethge W, Storb R, Maloney DG, Sandmaier BM.

Biol Blood Marrow Transplant. 2018 Feb;24(2):308-313. doi: 10.1016/j.bbmt.2017.10.016. Epub 2017 Oct 12.

19.

Increase of Intermediate Monocytes in Graft-versus-Host Disease: Correlation with MDR1+Th17.1 Levels and the Effect of Prednisolone and 1α,25-Dihydroxyvitamin D3.

Reinhardt-Heller K, Hirschberg I, Lang P, Vogl T, Handgretinger R, Bethge WA, Holzer U.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2057-2064. doi: 10.1016/j.bbmt.2017.08.008. Epub 2017 Aug 12.

20.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.

21.

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.

Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, Heim D, Bertz H, Grishina O, Socie G.

Lancet Haematol. 2017 Jun;4(6):e293-e301. doi: 10.1016/S2352-3026(17)30081-9.

PMID:
28583289
22.

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. Epub 2017 May 17.

23.

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

Schneidawind C, Duerr-Stoerzer S, Faul C, Kanz L, Weisel K, Bethge W, Schneidawind D.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12994. Epub 2017 May 26.

PMID:
28470884
24.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T.

J Clin Oncol. 2017 Jul 1;35(19):2157-2164. doi: 10.1200/JCO.2016.70.7349. Epub 2017 May 2.

25.

Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.

Haen SP, Groh C, Schumm M, Backert L, Löffler MW, Federmann B, Faul C, Dörfel D, Vogel W, Handgretinger R, Kanz L, Bethge WA.

Ann Hematol. 2017 May;96(5):817-827. doi: 10.1007/s00277-017-2941-x. Epub 2017 Feb 28.

PMID:
28247058
26.

Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.

Haen SP, Eyb V, Mirza N, Naumann A, Peter A, Löffler MW, Faul C, Vogel W, Bethge WA, Rammensee HG, Kanz L, Heni M.

J Cancer Res Clin Oncol. 2017 May;143(5):759-771. doi: 10.1007/s00432-017-2348-z. Epub 2017 Feb 16.

PMID:
28210842
27.

Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft-host interaction.

Mirza N, Zierhut M, Korn A, Bornemann A, Vogel W, Schmid-Horch B, Bethge WA, Stevanović S, Salih HR, Kanz L, Rammensee HG, Haen SP.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13827-13832. Epub 2016 Nov 10.

28.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.

Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2017 Jan;23(1):44-52. doi: 10.1016/j.bbmt.2016.09.027. Epub 2016 Oct 5.

29.

[Allogeneic stem cell transplantation : An option for autoimmune diseases?]

Wirths S, Bethge W, Henes JC.

Z Rheumatol. 2016 Oct;75(8):780-785. Review. German.

PMID:
27596146
30.

Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Ecsedi M, Schmohl J, Zeiser R, Drexler B, Halter J, Medinger M, Duyster J, Kanz L, Passweg J, Finke J, Bethge W, Lengerke C.

Ann Hematol. 2016 Oct;95(10):1627-36. doi: 10.1007/s00277-016-2758-z. Epub 2016 Aug 2.

PMID:
27480090
31.

Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?

Haen SP, Pham M, Faul C, Dörfel D, Vogel W, Kanz L, Bethge WA.

Blood Cancer J. 2016 Jul 8;6(7):e443. doi: 10.1038/bcj.2016.54. No abstract available.

32.

[Gastrointestinal complications in hematological patients].

Kurucay M, Kloth C, Bethge W, Faul C, Horger M.

Rofo. 2016 Jul;188(7):619-24. doi: 10.1055/s-0042-102755. Epub 2016 Jun 29. Review. German. No abstract available.

33.

EBV-negative aggressive B-cell lymphomas of donor origin after allogeneic hematopoietic stem cell transplantation: a report of three cases.

Federmann B, Bonzheim I, Schittenhelm J, Quintanilla-Martínez L, Mankel B, Vogel W, Faul C, Bethge W, Fend F.

Leuk Lymphoma. 2016 Nov;57(11):2603-11. doi: 10.3109/10428194.2016.1160088. Epub 2016 Apr 6.

PMID:
27049896
34.

Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.

Schmohl JU, Groh C, Faul C, Vogel W, Möhle R, Wirths S, Schneidawind D, Kanz L, Bethge WA.

Ann Hematol. 2016 May;95(6):973-83. doi: 10.1007/s00277-016-2644-8. Epub 2016 Mar 28.

PMID:
27021303
35.

Soluble heat shock protein 70 members in patients undergoing allogeneic hematopoietic cell transplantation.

Mirza N, Prokop L, Kowalewski D, Gouttefangeas C, Faul C, Bethge WA, Vogel W, Kanz L, Rammensee HG, Haen SP.

Transpl Immunol. 2016 May;36:25-31. doi: 10.1016/j.trim.2016.03.003. Epub 2016 Mar 25.

PMID:
27020764
36.

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.

Heinzelmann F, Bethge W, Beelen DW, Engelhard M, Kröger N, Dreger P, Niederwieser D, Finke J, Bunjes D, Tischer J, Kobbe G, Holler E, Bornhäuser M, Stelljes M, Baurmann H, Müller A, Haubitz I, Schrezenmeier H, Müller C, Ottinger H.

Bone Marrow Transplant. 2016 May;51(5):654-62. doi: 10.1038/bmt.2015.348. Epub 2016 Feb 8.

PMID:
26855152
37.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F.

N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002.

38.

Impulsivity-focused group intervention to reduce binge eating episodes in patients with binge eating disorder: study protocol of the randomised controlled IMPULS trial.

Schag K, Leehr EJ, Martus P, Bethge W, Becker S, Zipfel S, Giel KE.

BMJ Open. 2015 Dec 18;5(12):e009445. doi: 10.1136/bmjopen-2015-009445.

39.

Noninfectious Generalized Bronchiolitis in the Setting of Allogeneic Stem Cell Transplantation: A Potential Mimic of Lower Respiratory Tract Infection.

Kloth C, Grosse U, Wirths S, Gatidis S, Bethge W, Nikolaou K, Horger M.

Acad Radiol. 2015 Dec;22(12):1546-54. doi: 10.1016/j.acra.2015.08.025. Epub 2015 Oct 9.

PMID:
26482262
40.

Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.

Schneidawind D, Federmann B, Buechele C, Helwig A, Schmohl J, Vogel W, Faul C, Kanz L, Bethge WA.

Ann Hematol. 2016 Jan;95(1):115-124. doi: 10.1007/s00277-015-2512-y. Epub 2015 Sep 28.

PMID:
26411736
41.

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).

Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer RG, Bethge W, Kobbe G, Ayuk F, Gökbuget N, Hölzer D, Zander A, Beelen D.

Bone Marrow Transplant. 2015 Dec;50(12):1503-7. doi: 10.1038/bmt.2015.202. Epub 2015 Sep 14.

PMID:
26367236
42.

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Leukemia. 2016 Feb;30(2):261-7. doi: 10.1038/leu.2015.226. Epub 2015 Aug 18.

PMID:
26283567
43.

Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.

Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W.

J Cancer Res Clin Oncol. 2015 Dec;141(12):2241-51. doi: 10.1007/s00432-015-2027-x. Epub 2015 Aug 14.

PMID:
26272482
44.

Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT.

Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J, Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T.

Blood. 2015 Mar 19;125(12):1986-94. doi: 10.1182/blood-2014-06-573725. Epub 2015 Jan 23.

45.

Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60.

Federmann B, Faul C, Meisner C, Vogel W, Kanz L, Bethge WA.

Bone Marrow Transplant. 2015 Mar;50(3):427-31. doi: 10.1038/bmt.2014.292. Epub 2015 Jan 19.

PMID:
25599161
46.

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.

Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM.

Haematologica. 2014 Oct;99(10):1624-31. doi: 10.3324/haematol.2014.108340. Epub 2014 Aug 1.

47.

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD.

Bethge WA, Kerbauy FR, Santos EB, Gooley T, Storb R, Sandmaier BM.

Bone Marrow Transplant. 2014 Sep;49(9):1198-204. doi: 10.1038/bmt.2014.137. Epub 2014 Jul 21.

48.

KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.

Michaelis SU, Mezger M, Bornhäuser M, Trenschel R, Stuhler G, Federmann B, Oevermann L, Kanz L, Handgretinger R, Bethge WA.

Ann Hematol. 2014 Sep;93(9):1579-86. doi: 10.1007/s00277-014-2084-2. Epub 2014 Apr 26.

PMID:
24771045
49.

Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD.

Rieber N, Wecker I, Neri D, Fuchs K, Schäfer I, Brand A, Pfeiffer M, Lang P, Bethge W, Amon O, Handgretinger R, Hartl D.

Bone Marrow Transplant. 2014 Apr;49(4):545-52. doi: 10.1038/bmt.2013.236. Epub 2014 Jan 27.

PMID:
24464140
50.

Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation.

Stift J, Baba HA, Huber E, Federmann B, Fischer HP, Schmitt-Graeff A, Baurmann H, Bethge W, Schirmacher P, Wrba F, Greinix H, Fend F, Schwerdtfeger R, Shulman HM, Wolff D, Longerich T; Liver Pathology Group of the German-Austrian-Swiss Working Group on GvHD.

Virchows Arch. 2014 Feb;464(2):175-90. doi: 10.1007/s00428-013-1528-8. Epub 2014 Jan 3.

PMID:
24385287

Supplemental Content

Loading ...
Support Center